Association of PI-RADS categories and PSA density with active surveillance progression in patients with prostate cancer.
Lists
Only you see this
Abstract
293 Background: Active surveillance (AS) is now considered a well-accepted alternative for low-favorable intermediate risk prostate cancer over definitive therapy. Few studies have incorporated the use of multi-parametric MRI (mpMRI) into the treatment paradigm. In this study we investigate imaging findings that are predictive of a patient dropping off AS. Methods: Our institutional database was queried for all patients who met criteria for active surveillance from 11/2003 to 5/2017. Criteria for inclusion included ≥ 2 mpMRIs, ≥ 2 prostate biopsies, and a diagnosis of Gleason Grade group (GG) 1 or higher. Patients were excluded if they received any other therapy for the treatment of their prostate cancer such as radiation, chemotherapy, focal therapy, or immunologic therapy. Patient demographics, mpMRI, biopsy and most recent follow-up data were recorded. Factors, including PSA density (PSAD), PSA, lesion size, and PI-RADS category, associated with AS progression were evaluated in Cox Proportional Hazards Model. Results: An analysis of a total of 212 patients were performed during the study time interval. 88 patients were dropped from AS during this time and of those patients the median amount of time before removal was 4.70 years (range, 0.7-10.5). On univariable analysis, PI-RADS category (HR, 1.302 for every increase in 1 unit of the PI-RADS category; 95% CI, 1.046-1.62, p = 0.01) and PSAD (HR, 4.98 for every increase in 0.001 ng/mL/cc; 95% CI, 2.127-11.66; p < 0.001) were found to be associated with being removed from AS. On multivariable analysis, both PI-RADS score (HR, 1.281 for every increase in 1 unit of the PI-RADS category; 95% CI, 1.025-1.6; p = 0.003) and PSAD (HR, 4.188 for every increase in 0.001 ng/mL/cc; 95% CI, 1.640-10.7; p < 0.001) remained associated with being removed from AS. Conclusions: PI-RADS categories and PSAD predict the risk of a patient to drop off active surveillance. AS. Patients with these criteria should be considered high risk in any current AS protocol.[Table: see text]
BibTeX
@article{wang2020association,
author = {Alex Z. Wang and Luke O’Connor and Nitin Yerram and Johnathan Zeng and Sherif Mehralivand and Stephanie Harmon and Sandeep Gurram and Heather J. Chalfin and Siobhan Telfer and Amir H. Lebastchi and Michael Ahdoot and Patrick Gomella and Maria J. Merino and Barış Türkbey and Bradford J. Wood and Peter L. Choyke and Peter A. Pinto},
title = {{Association of PI-RADS categories and PSA density with active surveillance progression in patients with prostate cancer.}},
journal = {Journal of Clinical Oncology},
year = {2020},
doi = {10.1200/jco.2020.38.6\_suppl.293},
}Loading related content...